Navigation Links
Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
Date:6/27/2011

ect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and t
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 24 marks ASEA's "Meet ASEA" grand ... manufacturer of the world's first and only redox signaling ... , The Mexico City event features renowned speakers Dr. ... Field Leader Shawn Catmull from Draper, UT. , Dr. ... from the University of Utah and devotes his career ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... Sept. 17, 2014 Intarcia Therapeutics, Inc. ... from a study of the cost and predictability of ... th Annual Meeting of the European Association for ... today, Christian Frois , Ph.D., of Analysis Group, ... of planned Intarcia-sponsored, retrospective studies to characterize the prevalence ...
Breaking Biology Technology:Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... Gen-Probe Incorporated (NASDAQ: GPRO ) announced today ... results on Thursday, April 28, 2011 at approximately 4:00 pm ... conference call with management at 4:30 pm ET.   ... be accessed on the investors section of the Company,s web ...
... 14, 2011 /PRNewswire-Asia/ -- Global Pharm Holdings Group, Inc. ... or the "Company"), a Shenzhen-based, leading vertically integrated pharmaceutical ... its subsidiaries in Anhui, Jilin, and Shandong provinces, today ... 31, 2010. Fiscal Year 2010 Highlights ...
... TRIANGLE PARK, N.C., April 14, 2011 Talecris Biotherapeutics Holdings ... quarter earnings release after the market closes on April 27, ... will not be hosting a conference call to discuss its ... Inspiration. Dedication. Innovation. Talecris ...
Cached Biology Technology:Gen-Probe Announces Webcast of First Quarter 2011 Earnings Conference Call 2Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 2Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 3Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 4Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 5Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 6Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 7Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 8Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 9
(Date:9/16/2014)... Researchers at the Columbia Center for Children,s Environmental Health ... first to demonstrate an association between childhood asthma and ... array of household products. Results appear online in the ... born to mothers exposed during pregnancy to higher levels ... (DnBP) had a 72 percent and 78 percent increase ...
(Date:9/16/2014)... neuroscientists have discovered the "molecular brakes" that time the ... of mice. These "hair cells" translate sound waves into ... are interpreted as sounds. If the arrangement of the ... summary of the research will be published in ... "The proteins Hey1 and Hey2 act as brakes to ...
(Date:9/16/2014)... EUGENE, Ore. -- Each tree species has its own ... researchers and colleagues from other institutions who studied the ... growing on a Panamanian island. , "This study demonstrates ... plant families and with different ecological strategies possess very ... Steven W. Kembel, a former postdoctoral researcher in the ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Microbiome research shows each tree species has a unique bacterial identity 2
... WEST LAFAYETTE, Ind. - Researchers at Purdue University have ... in spinal cord injuries using nano-spheres that could be ... The synthetic "copolymer micelles" are drug-delivery spheres about 60 ... the diameter of a red blood cell. Researchers ...
... To celebrate the 150th anniversary this month of ... American Institute of Biological Sciences (AIBS) is publishing open ... historic insights into evolution. , The two articles are ... and James T. Costa of Western Carolina University. Padian,s ...
... The National Association of Biology Teachers (NABT) will ... at Naugatuck Valley Community College (NVCC) in Waterbury, ... the NABT annual professional development conference to be ... The Evolution Education Award is cosponsored by the ...
Cached Biology News:Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Biologists, educators recognize excellence in evolution education 2
...
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
... custom microplate coating using advanced automated high throughput microplate processing ... We can also accommodate virtually any lot size of the ... , 8 and 12 well ... 384 well microplate, ...
...
Biology Products: